Skip to main content
OpenTrials
Completed

NCT Number: NCT03948295

Lipid Challenge in Adults

Participants in this study will have one visit to the Emory University Hospital Clinical Research Unit. Participants will consume, over 5 minutes, a single standardized fat challenge (100 grams), using a commercially available liquid high-energy long chain triglyceride fat emulsion (Calogen), which provides 50 grams of long chain triglycerides per 100 mL. Participants will have 20 mL blood withdrawn at six successive time points over an 8-hour period, where the first time point after fasting (baseline) is followed by 5 time-points after fat consumption. Blood will be analyzed for a wide panel of blood lipids.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiovascular Diseases

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Emory University Hospital

Atlanta, Georgia, 30322, United States

About this study

Cardiovascular disease (CVD) is the leading killer of Americans, accounting more than 800,000 deaths each year. A vital step in reducing the number of heart disease-related deaths in the U.S. is to identify those at probable risk. The Clinical Chemistry Branch (CCB) in the Division of Laboratory Sciences (DLS) at the Centers for Disease Control and Prevention (CDC) has developed advanced analytical methods for assessing the risk for lipid metabolism related diseases, including CVD. CCB of the CDC has developed a comprehensive analytical method to measure levels of protein and lipid constituents of lipoprotein size/density classes (e.g. high-density lipoprotein (HDL), low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) in blood. CCB plans to eventually apply this method in future investigations of cohorts with different CVD states. The measurement of this wide array of CVD-linked biomarkers has the potential to improve the assessment of CVD risk over current clinical methods based on lipoprotein classes.

However, limited information is available about how the advanced tests developed by CCB are affected by blood collection conditions, such as fasting/non-fasting state of the subjects. The purpose of this study is to determine the relative significance of these pre-analytical variables and determine optimal conditions for future cohort studies.

This study will recruit up to 32 healthy individuals, with and without obesity, to participate. The study involves one visit to the Emory University Hospital Clinical Research Unit where participants will consume, over 5 minutes, a single standardized fat challenge (100 grams), using a commercially available liquid high-energy long chain triglyceride fat emulsion (Calogen; http://www.nutricia.ie/calogen#), which provides 50 grams of long chain triglycerides per 100 mL. Participants will have 20 mL blood withdrawn at six successive time points over an 8-hour period, where the first time point after fasting is followed by 5 time-points after fat (Calogen) consumption. Blood will be analyzed at the CCB for a wide panel of blood lipids and potential biomarkers for CVD.

Specific expected outcomes of the study include the following: 1) Determination of typical intra-individual differences between fasting and post-prandial states; and 2) Changes in the levels of the various analytes after fat consumption will be indicative of inter-individual differences in the rate of triglyceride depletion, and the rate of accumulation/depletion of HDL or LDL of different particle size range and composition. The results will allow the assessment of significant differences in lipid metabolism between individuals with a normal BMI (20 to 25 kg/m^2) versus those with a BMI in the obese range (30-35 kg/m^2).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • functionally ambulatory
  • BMI between >20 to 40 kg/m^2
  • available for an 8 hour visit to the Emory University Hospital Clinical Research Center

Exclusion criteria

  • has taken any diabetic or lipid lowering prescription medications within the past 12 months
  • history of chronic diseases
  • hospitalized within the last year
  • currently pregnant
  • current active malignant neoplasm or history of malignancy (other than localized basal cell cancer of the skin) during the previous 5 years
  • current chronic autoimmune or pro-inflammatory disease
  • history of tuberculosis, HIV, or other chronic infection
  • previous diagnosis of type 1 or type 2 diabetes with active treatment with insulin or other glucose lowering medication
  • advanced (>= stage 3) renal disease
  • recreational or prescription drug or alcohol abuse
  • any history of gastrointestinal diseases, including malabsorption
  • any history of intolerance to dietary fat
  • inability to provide informed consent

Treatment and study plan

Lipid Challenge

Dietary Supplement

After fasting for 10 hours, all participants will undergo a lipid challenge with Calogen. Calogen is a commercially available liquid high-energy long chain triglyceride fat emulsion used to fortify foods. Calogen provides 50 grams of long chain triglycerides per 100 mL. Participants must avoid physical activity during the 6 hour study period to avoid changes in metabolism that could affect the results of the study.

Other names: Calogen

Primary outcomes

  1. Change in high-density lipoprotein (HDL) Size

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    HDL concentration size profiles for each time-point will be compared between participants with normal BMI and participants with obese range BMI. HDL is considered to be anti-atherogenic because of its ability deplete excess cholesterol accumulating necrotic cores and repair arterial lesions.

  2. Change in low-density lipoprotein (LDL) Size

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    LDL concentration size profiles for each time-point will be compared between participants with normal BMI and participants with obese range BMI. LDL is considered to be atherogenic because it is likely to be trapped inside the intima of blood vessels and arteries and initiate inflammatory response, foam-cell formation, and smooth muscle cell proliferation, leading to development necrotic cores, lesions, plaques and their eventual rupture. Elevated LDL has been thought to contribute to atherosclerotic events, however, research has also observed coronary events occurring in individuals with LDL levels in the acceptable range.

  3. Change in Total Cholesterol

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Total cholesterol profiles for each time-point will be compared between participants with normal BMI and participants with obese range BMI. Elevated total cholesterol has been thought to contribute to atherosclerotic events, however, research has also observed coronary events occurring in individuals with total cholesterol levels in the acceptable range.

  4. Change in Free Cholesterol

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Free cholesterol concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI. Free cholesterol is unesterified cholesterol that is circulating in the blood stream.

  5. Change in Cholesterol Ester

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Cholesterol ester concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI. Lipoproteins contain cholesterol ester, and cholesterol ester is associated with atherosclerosis.

  6. Change in Triglycerides

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Triglyceride concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI. Triglycerides peak in serum 2 to 4 hours after a meal and return to a pre-meal state in 6 to 8 hours.

  7. Change in Phosphatidylinositol

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Phosphatidylinositol concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  8. Change in Phosphatidylethanolamine

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Phosphatidylethanolamine concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  9. Change in Phosphatidylcholine

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Phosphatidylcholine concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  10. Change in Sphingomyelin

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Sphingomyelin concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  11. Change in Lysophosphatidylcholine

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Lysophosphatidylcholine concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  12. Change in Apolipoprotein AI

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Apolipoprotein AI concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  13. Change in Apolipoprotein AII

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Apolipoprotein AII concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  14. Change in Apolipoprotein AIV

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Apolipoprotein AIV concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  15. Change in Apolipoprotein B

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Apolipoprotein B concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  16. Change in Apolipoprotein CI

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Apolipoprotein CI concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  17. Change in Apolipoprotein CII

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Apolipoprotein CII concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  18. Change in Apolipoprotein CIII

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Apolipoprotein CIII concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  19. Change in Apolipoprotein E

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Apolipoprotein E concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  20. Change in Lecithin-Cholesterol Acyltransferase

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Lecithin-cholesterol acyltransferase concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  21. Change in Cholesterol Ester Transfer Protein

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Cholesterol ester transfer protein concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  22. Change in Lipoprotein (a)

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Lipoprotein (a) concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  23. Change in Phospholipid Transfer Protein

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Phospholipid transfer protein concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  24. Change in Serum Paraoxonase/arylesterase 1

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Serum paraoxonase/arylesterase 1 concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  25. Change in Serum Amyloid A1

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Serum amyloid A1 concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

  26. Change in Serum Amyloid A4

    Time frame: Hours 0, 0.5, 1, 2, 4, and 6

    Serum amyloid A4 concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.

Sponsors and collaborators

Lead sponsor

Emory University

Other

Collaborators

  • Centers for Disease Control and Prevention

Registry information

Official study title

Measurements of Lipoproteins, Apolipoproteins and Lipids - Determination of Pre-analytical Variables for Analysis of Blood Collected From Fasting and Post-prandial Subjects

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
May 13, 2019
Registry last updated
May 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.